AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01908699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
Trial: NCT01084551
Drug: SPM 962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks
Trial: NCT01084551
Drug: SPM 962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks
Trial: NCT01084551
Drug: Placebo of SPM 962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a daily transdermal administration for 13 weeks
Trial: NCT00836901
Drug: Augmentin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg-57 mg chewable tablet
Trial: NCT04250207
Drug: K-321 Solution
RxNorm normalized name: K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-321 solution drops
Trial: NCT04250207
Drug: Placebo Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution drops for K-321
Trial: NCT03945253
Drug: ASP8374
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous
Trial: NCT03464461
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV drug
Trial: NCT03263390
Drug: Anti Obesity Drugs
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response to FDA approved anti obesity medications
Trial: NCT01687595
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phosphate buffered saline
Trial: NCT02524899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in placebo arm will have matching schedule as active arm.
Trial: NCT00706537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as two tablets once daily for three weeks
Trial: NCT03422887
Drug: Nalbuphine and Flurbiprofen Axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine and Flurbiprofen Axetil administration during surgery
Trial: NCT00773591
Drug: NT 201, a Botulinum neurotoxin type A, free of complexing proteins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.
Trial: NCT03633487
Drug: Mucinex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucinex® 1200 mg ER Bi-Layer tablet
Trial: NCT00667979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT03480750
Drug: pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegylated liposomal doxorubicin 40mg/m2 IV D1
Trial: NCT03419624
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet once daily
Trial: NCT03419624
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection once weekly
Trial: NCT00236795
Drug: norelgestromin + ethinyl estradiol; triphasil.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00549211
Drug: GSK557296
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02397473
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00019760
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01922895
Drug: Placebo for Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule manufactured without active ingredients.
Trial: NCT01916226
Drug: FPNS
RxNorm normalized name: Fluticasone Propionate and Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
Trial: NCT01916226
Drug: FPNS Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
Trial: NCT01170754
Drug: PEG-3350 and Gatorade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation.
Trial: NCT01170754
Drug: Golytely 4 liters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golytely 4 liters
Trial: NCT04086290
Drug: ADT
RxNorm normalized name: Radtue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
Trial: NCT00020007
Drug: isolated perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00421967
Drug: Ropivacaine, Ketorolac, adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration: 150 ml Ropivacaine 2mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml Adrenaline 1 mg/ml Intraarticular infusion: 4 ml/h 384 mg Ropivacaine 60 mg Ketorolac
Trial: NCT00421967
Drug: Ropivacaine Ketorolac
RxNorm normalized name: CLONIDINE/KETOROLAC/ROPIVACAINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion: 4 ml/h 384 mg Ropivacaine I.V. Ketorolac 90 mg
Trial: NCT02420314
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Administered intravenously (IV)~* 75g per infusion~* Two infusions per week~* 1 cycle is 3 weeks~* given up to 4 cycles~* may be given while chemotherapy if delayed due to low counts
Trial: NCT02062684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02594579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
Trial: NCT02915601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03019653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
Trial: NCT01848457
Drug: High-dose methotrexate infusion duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
Trial: NCT02770365
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03620981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 1 tablet /day Once daily for 10 weeks
Trial: NCT03105765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.
Trial: NCT00257933
Drug: Prednisolone high dose
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg/kg/day orally divided every 6 hours (maximum 30 mg per dose)
Trial: NCT00257933
Drug: Prednisolone lower dose
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg/kg/day orally divided q 12 (maximum 30mg/dose) alternating with placebo
Trial: NCT03947385
Drug: IDE196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDE196 dosed orally, twice daily for each 28-day cycle
Trial: NCT01878474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose in Caucasian men
Trial: NCT01878474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age-effect in Caucasian men
Trial: NCT01878474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gender-effect in Caucasian women
Trial: NCT01878474
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose in Japanese men
Trial: NCT03228043
Drug: CAPEOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPEOX adjuvant chemotherapy for resectable colorectal
Trial: NCT01097681
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03973489
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.
Trial: NCT01887600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
Trial: NCT02006836
Drug: met or diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In diabetic group, 20 diabetic patients were included for GI measurement , 18 of whom were on metformin treatment. Only 2 patients were on diet control due to the early stage of this disease.
Trial: NCT02797548
Drug: Aspirin only
RxNorm normalized name: Aspirin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin only during surgery
Trial: NCT02797548
Drug: No antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet therapy will be during surgery
Trial: NCT01610401
Drug: Pretreatment with metformin in combination of infusion of caffeine.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement
Trial: NCT01610401
Drug: No pretreatment with metformin in combination with infusion of caffeine
RxNorm normalized name: acetaminophen / butalbital / caffeine / codeine Oral Capsule [Fioricet with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).
Trial: NCT00107614
Drug: DT PACE + Rituxan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with \< 50% response to induction) OR MEL-DT PACE (Patients with \> 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
Trial: NCT01117662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous application of placebo (NaCl 0,9 %) matching active treatment
Trial: NCT03638180
Drug: BLU-5937
RxNorm normalized name: Blu-Kote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLU-5937 oral tablet
Trial: NCT03638180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to BLU-5937
Trial: NCT04109482
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 300 - 500 mg/m2/day IV (3 days) on days -5, -4, and -3
Trial: NCT04505787
Drug: Esflurbiprofen hydrogel patch 165 mg (EFHP)
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patch application with PK blood sampling
Trial: NCT04505787
Drug: Froben 100 mg comprimidos revestidos
RxNorm normalized name: flurbiprofen 100 MG [Froben]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet administration with PK blood sampling
Trial: NCT02584738
Drug: Nebulized Magnesium Sulfate
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours.
Trial: NCT02584738
Drug: Nebulized isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours.
Trial: NCT02584738
Drug: Methylprednisolone or Prednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
Trial: NCT03362632
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observation study, no specific antibiotics will be indicated during treatment.
Trial: NCT01073709
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00267046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose 3 days prior to chemotherapy
Trial: NCT00615160
Drug: PTK787/ZK 222584
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
Trial: NCT02944045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline serum
Trial: NCT00839930
Drug: Pletal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 50 mg, single-dose tablet
Trial: NCT00859885
Drug: Antithrombotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiplatelets, anticoagulants
Trial: NCT02386072
Drug: antimuscarinic medication
RxNorm normalized name: ANTIMUSCARINICS/ANTISPASMODICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00693108
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01592747
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, oral administration.
Trial: NCT02957903
Drug: Isotonic Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
Trial: NCT00176826
Drug: Myeloablative conditioning regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
Trial: NCT00770796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01982747
Drug: MGN-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01982747
Drug: Placebo-MGN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01258699
Drug: Thiocacid HR Tab 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg for 1 day
Trial: NCT03410771
Drug: Monitor antibiotic exposure (PK profile)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: several plasma samples to measure drug exposure
Trial: NCT02088411
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02134808
Drug: Creatine
RxNorm normalized name: Creatine
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Creatine is a nutritional supplement.
Trial: NCT02134808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
Trial: NCT01475825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vehicle for subcutaneous injection.
Trial: NCT04157738
Drug: Rapid-Acting Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)
Trial: NCT04157738
Drug: Long acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to discharge, all subjects will receive a regimen that includes a daily dose of long-acting insulin (Glargine)
Trial: NCT00001482
Drug: Gabapentin (Neurontin® (Registered Trademark))
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02096926
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02096926
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg PO
Trial: NCT02934217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single intravenous bolus injection of Placebo
Trial: NCT01347086
Drug: Matching placebo (low dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of matching placebo
Trial: NCT01347086
Drug: Matching placebo (medium dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of matching placebo
Trial: NCT01347086
Drug: Matching placebo (high dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of matching placebo
Trial: NCT01364662
Drug: SPN-810
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT01364662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT02197065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02264821
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo in spinal anaesthesia and in wound infiltration
Trial: NCT04937621
Drug: Treatment data collect
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline treatment data as well as follow-up treatment data are collected
Trial: NCT02067156
Drug: G-202
RxNorm normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
Trial: NCT01704989
Drug: Prostagladin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be initiated with latanoprost 0.005%. At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (\>35 mmHg) or advanced damage at presentation.
Trial: NCT04424251
Drug: Experimental: stage I：HSK21542 0.4 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
Trial: NCT04424251
Drug: Experimental: stage I：HSK21542 1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once preoperative and once each at 0, 8, and 16 h postoperative, for a total of 4 administrations
Trial: NCT04424251
Drug: Experimental: stage I：HSK21542 0.5μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Trial: NCT04424251
Drug: Experimental: stage I：HSK21542 1μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Trial: NCT04424251
Drug: Experimental: stage II：HSK21542 0.5μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Trial: NCT04424251
Drug: Experimental: stage II：HSK21542 1μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Trial: NCT04424251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once each at 0, 8, and 16 h postoperative, for a total of 3 administrations
Trial: NCT03760081
Drug: ASP1650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received ASP1650 dose level 1 or dose level 2 as intravenous infusion, Q2W starting on C1D1 for up to a maximum of 12 cycles or until study discontinuation criterion was met, whichever occurred earlier. Duration of each treatment cycle was 14 days.